Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1998-01-22
2002-05-07
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S002600, C536S023500, C536S023700, C435S006120, C435S173300, C435S069100, C435S243000, C424S093100
Reexamination Certificate
active
06384018
ABSTRACT:
BACKGROUND OF THE INVENTION
A major obstacle to the development of vaccines against viruses and bacteria, particularly those with multiple serotypes or a high rate of mutation, against which elicitation of neutralizing antibodies and/or protective cell-mediated immune responses is desirable, is the diversity of the external proteins among different isolates or strains. Since cytotoxic T-lymphocytes (CTLs) in both mice and humans are capable of recognizing epitopes derived from conserved internal viral proteins [J. W. Yewdell et al.,
Proc. Natl. Acad. Sci.
(
USA
) 82, 1785 (1985); A. R. M. Townsend, et al.,
Cell
44, 959 (1986); A. J. McMichael et al.,
J. Gen. Virol
. 67, 719 (1986); J. Bastin et al.,
J. Exp. Med
. 165, 1508 (1987); A. R. M. Townsend and H. Bodmer,
Annu. Rev. Immunol
. 7, 601 (1989)], and are thought to be important in the immune response against viruses [Y.-L. Lin and B.A. Askonas,
J. Exp. Med
. 154, 225 (1981); I. Gardner et al.,
Eur. J. Immunol
. 4, 68 (1974); K. L. Yap and G. L. Ada,
Nature
273, 238 (1978); A. J. McMichael et al.,
New Engl. J. Med
. 309, 13 (1983); P. M. Taylor and B. A. Askonas, Immunol. 58, 417 (1986)], efforts have been directed towards the development of CTL vaccines capable of providing heterologous protection against different viral strains.
It is known that CTLs kill virally- or bacterially-infected cells when their T cell receptors recognize foreign peptides associated with MHC class I and/or class II molecules. These peptides can be derived from endogenously synthesized foreign proteins, regardless of the protein's location or function within the pathogen. By recognition of epitopes from conserved proteins, CTLs may provide heterologous protection. In the case of intracellular bacteria, proteins secreted by or released from the bacteria are processed and presented by MHC class I and II molecules, thereby generating T-cell responses that may play a role in reducing or eliminating infection.
Most efforts to generate CTL responses have either used replicating vectors to produce the protein antigen within the cell [J. R. Bennink et al.,
ibid
. 311, 578 (1984); J. R. Bennink and J. W. Yewdell,
Top. Microbiol. Immunol
. 163, 153 (1990); C. K. Stover et al.,
Nature
351, 456 (1991); A. Aldovini and R. A. Young,
Nature
351, 479 (1991); R. Schafer et al.,
J. Immunol
. 149, 53 (1992); C. S. Hahn et al.,
Proc. Natl. Acad. Sci.
(
USA
) 89, 2679 (1992)], or they have focused upon the introduction of peptides into the cytosol [F. R. Carbone and M. J. Bevan,
J. Exp. Med
. 169, 603 (1989); K. Deres et al.,
Nature
342, 561 (1989); H. Takahashi et al.,
ibid
. 344, 873 (1990); D. S. Collins et al.,
J. Immunol
. 148, 3336 (1992); M. J. Newman et al.,
ibid
. 148, 2357 (1992)]. Both of these approaches have limitations that may reduce their utility as vaccines. Retroviral vectors have restrictions on the size and structure of polypeptides that can be expressed as fusion proteins while maintaining the ability of the recombinant virus to replicate [A. D. Miller,
Top. Microbiol. Immunol
. 158, 1 (1992)], and the effectiveness of vectors such as vaccinia for subsequent immunizations may be compromised by immune responses against vaccinia [E. L. Cooney et al.,
Lancet
337, 567 (1991)]. Also, viral vectors and modified pathogens have inherent risks that may hinder their use in humans [R. R. Redfield et al.,
New Engl. J. Med
. 316, 673 (1987); L. Mascola et al.,
Arch. Intern. Med
. 149, 1569 (1989)]. Furthermore, the selection of peptide epitopes to be presented is dependent upon the structure of an individual's MHC antigens and, therefore, peptide vaccines may have limited effectiveness due to the diversity of MHC haplotypes in outbred populations.
Benvenisty, N., and Reshef, L. [
PNAS
83, 9551-9555, (1986)] showed that CaCl
2
precipitated DNA introduced into mice intraperitoneally (i.p.), intravenously (i.v.) or intramuscularly (i.m.) could be expressed. The intramuscular (i.m.) injection of DNA expression vectors in mice has been demonstrated to result in the uptake of DNA by the muscle cells and expression of the protein encoded by the DNA [J. A. Wolff et al.,
Science
247, 1465 (1990); G. Ascadi et al.,
Nature
352, 815 (1991)]. The plasmids were shown to be maintained episomally and did not replicate. Subsequently, persistent expression has been observed after i.m. injection in skeletal muscle of rats, fish and primates, and cardiac muscle of rats [H. Lin et al.,
Circulation
82, 2217 (1990); R. N. Kitsis et al.,
Proc. Natl. Acad. Sci.
(
USA
) 88, 4138 (1991); E. Hansen et al.,
FEBS Lett.
290, 73 (1991); S. Jiao et al.,
Hum. Gene Therapy
3, 21 (1992); J. A. Wolff et al.,
Human Mol. Genet
. 1, 363 (1992)]. The technique of using nucleic acids as therapeutic agents was reported in WO90/11092 (Oct. 4,1990), in which naked polynucleotides were used to vaccinate vertebrates.
Recently, the coordinate roles of B7 and the major histocompatibility complex (MHC) presentation of epitopes on the surface of antigen presenting cells in activating CTLs for the elimination of tumors was reviewed [Edgington,
Biotechnology
11, 1117-1119, 1993]. Once the MHC molecule on the surface of an antigen presenting cell (APC) presents an epitope to a T-cell receptor (TCR), B7 expressed on the surface of the same APC acts as a second signal by binding to CTLA-4 or CD28. The result is rapid division of CD4+helper T-cells which signal CD8+ T-cells to proliferate and kill the APC.
It is not necessary for the success of the method that immunization be intramuscular. Thus, Tang et al., [
Nature,
356, 152-154 (1992)] disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH antibodies in the mice. Furth et al., [
Analytical Biochemistry
, 205, 365-368, (1992)] showed that a jet injector could be used to transfect skin, muscle, fat, and mammary tissues of living animals. Various methods for introducing nucleic acids was recently reviewed [Friedman, T.,
Science
, 244, 1275-1281 (1989)]. See also Robinson et al., [
Abstracts of Papers Presented at the
1992
meeting on Modern Approaches to New Vaccines, Including Prevention of AIDS
, Cold Spring Harbor, p92; Vaccine 11, 957 (1993)], where the im, ip, and iv administration of avian influenza DNA into chickens was alleged to have provided protection against lethal challenge. Intravenous injection of a DNA:cationic liposome complex in mice was shown by Zhu et al., [
Science
261, 209-211 (Jul. 9, 1993); see also WO93/24640, Dec. 9, 1993] to result in systemic expression of a cloned transgene. Recently, Ulmer et al., [
Science
259, 1745-1749, (1993)] reported on the heterologous protection against influenza virus infection by injection of DNA encoding influenza virus proteins.
Wang et al., [
P.N.A.S. USA
90, 4156-4160 (May, 1993)] reported on elicitation of immune responses in mice against HIV by intramuscular inoculation with a cloned, genomic (unspliced) HIV gene. However, the level of immune responses achieved was very low, and the system utilized portions of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter and portions of the simian virus 40 (SV40) promoter and terminator. SV40 is known to transform cells, possibly through integration into host cellular DNA. Thus, the system described by Wang et al., is wholly inappropriate for administration to humans, which is one of the objects of the instant invention.
WO 93/17706 describes a method for vaccinating an animal against a virus, wherein carrier particles were coated with a gene construct and the coated particles are accelerated into cells of an animal.
Studies by Wolff et al. (supra) originally demonstrated that intramuscular injection of plasmid DNA encoding a reporter gene results in the expression of that gene in myocy
Content Jean
Huygen Kris
Liu Margaret A.
Montgomery Donna
Ulmer Jeffrey
Merck & Co. , Inc.
Minnifield Nita
Tribble Jack L.
Yablonsky Michael D.
LandOfFree
Polynucleotide tuberculosis vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotide tuberculosis vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotide tuberculosis vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2882450